1181680-69-2

Upstream product

• 1005768-69-3 (2R,3R)-3-O-benzyl-4,4-difluoro-5-hexene-1,2,3-triol 
• 1369405-71-9 (S)-2-((R)-1-(benzyloxy)-2,2-difluorobut-3-en-1-yl)oxirane 
• 1369405-72-0 (2S,3R)-3-(benzyloxy)-4,4-difluorohex-5-ene-1,2-diyl diacetate 
• 1369405-74-2 (2S,3R)-3-(benzyloxy)-1-((tert-butyldimethylsilyl)oxy)-4,4-difluorohex-5-en-2-ol 
• 1369405-75-3 (((2S,3R)-2,3-bis(benzyloxy)-4,4-difluorohex-5-en-1-yl)oxy)(tert-butyl)dimethylsilane 
• 1369405-76-4 C₂₆H₃₈F₂O₅Si 
• 1369405-77-5 (2R,4R,5S)-1,4,5-tris(benzyloxy)-6-((tert-butyldimethylsilyl)oxy)-3,3-difluorohexan-2-ol 
• 1369405-79-7 (2S,3R,5R)-2,3,6-tris(benzyloxy)-4,4-difluorohexane-1,5-diol 
• 1369405-80-0 (3R,4R,6R)-3,4-bis(benzyloxy)-6-((benzyloxy)methyl)-5,5-difluorotetrahydro-2H-pyran-2-one 
• 1369406-03-0 C₄₂H₄₁ClF₂O₆ 
• 1369405-70-8 (2R,3R)-3-(benzyloxy)-1-((tert-butyldimethylsilyl)oxy)-4,4-difluorohex-5-en-2-ol 
• 634181-78-5 (R)-4-((R)-1-(benzyloxy)-2,2-difluorobut-3-en-1-yl)-2,2-dimethyl-1,3-dioxolane 

Downstream Products

• 1181681-47-9 C₂₄H₂₇ClF₂O₇ 

Relevant academic research and scientific papers

Synthesis and biological evaluation of SGLT2 inhibitors: Gem-difluoromethylenated Dapagliflozin analogs

Dapagliflozin is currently the most advanced SGLT2 inhibitor, which has been used in Phase III clinical trials for treatment of diabetes. Here we describe the design and synthesis of Dapagliflozin analogs modified with gem-difluoromethylene group. Their b

Novel aromatic fluoroglycoside derivatives, pharmaceuticals comprising said compounds and the use thereof

The invention relates to substituted aromatic fluoroglycoside derivatives, and to the physiologically compatible salts and physiologically functional derivatives thereof. The invention also relates to methods of lowering blood sugar and the treatment of t